
    
      This is a multi-center, multi-cohort, open-label phase 1b/2 clinical study to evaluate the
      anti-tumor activity, safety, PK profile, immunogenicity and potential biomarkers of AK104
      plus lenvatinib for the treatment of advanced hepatocellular carcinoma.
    
  